OnKure Therapeutics (OKUR) Free Cash Flow (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Free Cash Flow data on file, last reported at -$12.9 million in Q1 2026.

• Quarterly Free Cash Flow rose 7.7% year-over-year to -$12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.8 million (up 6.89% YoY) and the FY2025 annual result came in at -$51.9 million, down 1.38% from the prior year.
• Free Cash Flow retreated to -$12.9 million in Q1 2026, from -$11.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $9.1 million in Q4 2023 to a low of -$23.4 million in Q4 2024.
• A 5-year average of -$11.7 million and a median of -$12.0 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 157.67% — and 2024, when it sank 355.45%.
• Tracing OKUR's Free Cash Flow over 5 years: stood at -$15.9 million in 2022, then soared by 157.67% to $9.1 million in 2023, then slumped by 355.45% to -$23.4 million in 2024, then jumped by 50.7% to -$11.5 million in 2025, then declined by 12.34% to -$12.9 million in 2026.
• The last three Free Cash Flow figures came in at -$12.9 million (Q1 2026), -$11.5 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.